{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzllgp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzllgp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/48\\\/2\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/48\\\/2\u0022}],\u0022ac\u0022:{\u0022spmdc;15\\\/48\\\/2\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;15\\\/48\\\/2\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/cdn\/css\/http\/css_Xg7z6oCTVgud_Q0huYz9x9iiD5H_2YPSJ5z2ZViSWdY.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\u003Cp id=\u0022p-1\u0022\u003EIn the past 30 years, hepatitis C virus therapy has progressed from toxic regimens with low efficacy that included injectable IFN-alfa to the present highly effective interferon-free oral regimens with low toxicity. Implementation of risk reduction policies and national control strategies is needed to eradicate hepatitis C virus.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Ehepatitis C virus\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Einterferon-free strategies\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EHCV genotypes\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Edirect-acting antiviral drugs\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Escreening\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eepidemiology\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eglobal control\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EHCV eradication\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eemerging therapies\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Einfectious diseases screening \u0026amp; prevention\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eviral infections\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\u003Cp id=\u0022p-2\u0022\u003EHepatitis C virus (HCV) affects between 130 and 150 million individuals worldwide and is associated with about 350\u2005000 to 500\u2005000 deaths annually [WHO. \u003Ca href=\u0022http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/\u0022\u003Ehttp:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/\u003C\/a\u003E. Accessed May 6, 2015]. Although antiviral therapies can cure HCV, access to diagnosis and treatment is low.\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EInterferon (IFN)-free strategies are proving highly effective for curing infections. With these treatment strategies, Jean-Michel Pawlotsky, MD, PhD, Henri Mondor Hospital, University of Paris-Est, Cr\u00e9teil, France, predicted that HCV infection will become a rare disease in 5 to 10 years, at least in high-income countries that implement a national control strategy.\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EHCV has been classified into 7 genotypes and 67 subtypes [Smith DB et al. \u003Cem\u003EHepatology\u003C\/em\u003E. 2014]. Genotype 1 subtypes 1a and 1b are the most common worldwide and account for about 60% of global infections [WHO. \u003Ca href=\u0022http:\/\/www.who.int\/csr\/disease\/hepatitis\/whocdscsrlyo2003\/en\/index2.html\u0022\u003Ehttp:\/\/www.who.int\/csr\/disease\/hepatitis\/whocdscsrlyo2003\/en\/index2.html\u003C\/a\u003E. Accessed May 6, 2015].\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003EAccording to Prof Pawlotsky, although HCV is an important public health problem, it is also the only chronic viral infection in humans that is curable. According to the latest European Association for the Study of the Liver (EASL) recommendations for treatment of HCV [EASL. \u003Cem\u003EJ Hepatol\u003C\/em\u003E. 2015], a cure is evidenced by undetectable levels of HCV RNA 12 and 24 weeks after the end of treatment (sustained virologic response [SVR] 12 and SVR24).\u003C\/p\u003E\u003Cp id=\u0022p-6\u0022\u003EOver the last 30 years, there has been great progress in the treatment of HCV genotype 1 (\u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E) [Pawlotsky JM et al. \u003Cem\u003EJ Hepatol\u003C\/em\u003E. 2015]. Early therapy using injectable IFN-alfa was associated with an SVR rate of only about 10%. This rate has increased to about 45% following the introduction of pegylated IFN and the addition of ribavirin (RBV). Most recently, the development of direct-acting antiviral (DAA) drugs has led to increased treatment success with a shorter course of treatment. As of 2014, oral treatment strategies free of IFN have achieved SVR response rates of 93% to 100% with as little as 12 weeks of therapy.\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022\/\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/16621\/expansion?postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 html=\u00221\u0022 fragment=\u0022#\u0022 external=\u00221\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/16621\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16621\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \u003Cp id=\u0022p-7\u0022 class=\u0022first-child\u0022\u003ESVR Rates for HCV Genotype 1 With Successive Treatment Strategies\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-9\u0022\u003ENew DAA drugs target specific steps in the HCV life cycle that result in disruption of viral replication and infection. Targets for viral inhibition include HCV polyprotein processing, replication, assembly, and release. There are 4 classes of DAA drugs: nonstructural proteins 3\/4A (NS3\/4A) protease inhibitors (PIs), nonstructural proteins 5B (NS5B) nucleoside polymerase inhibitors, NS5B nonnucleoside polymerase inhibitors, and nonstructural proteins 5A (NS5A) inhibitors.\u003C\/p\u003E\u003Cp id=\u0022p-10\u0022\u003EAccording to the EASL recommendations, therapy should be considered for treatment-na\u00efve and treatment-experienced patients with compensated or decompensated chronic liver disease related to HCV [EASL. \u003Cem\u003EJ Hepatol\u003C\/em\u003E. 2015]. Treatment should be prioritized based on clinical assessment. IFN-free regimens are recommended because of their virological efficacy, ease of use, and tolerability in HCV and HIV-coinfected patients with and without cirrhosis. Prior treatment experience, HCV genotype, severity of disease, comorbidities, pharmacokinetic profile, and drug-drug interactions play a role in treatment selection.\u003C\/p\u003E\u003Cp id=\u0022p-11\u0022\u003EIn one study in HCV patients with genotype 1 infection, once-daily ledipasvir (LDV; NS5A inhibitor)\/sofosbuvir (SOF; NS5B nucleoside polymerase inhibitor) with or without RBV in a single tablet for 12 or 24 weeks was highly effective in previously untreated patients (\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E) [Afdhal N et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E. 2014].\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/2\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022SOF\/LDV With or Without RBV Effective Treatment for Patients With Genotype 1 HCVHCV, hepatitis C virus; LDV, ledipasvir; RBV, ribavirin; SOF, sofosbuvir; SVR12, sustained virologic response at 12 weeks.Source: Afdhal N et al. N Engl J Med. 2014.Reproduced with permission from JM Pawlotsky, MD, PhD.\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1914553591\u0022 data-figure-caption=\u0022\u0026amp;lt;div xmlns=\u0026amp;quot;http:\/\/www.w3.org\/1999\/xhtml\u0026amp;quot;\u0026amp;gt;SOF\/LDV With or Without RBV Effective Treatment for Patients With Genotype 1 HCVHCV, hepatitis C virus; LDV, ledipasvir; RBV, ribavirin; SOF, sofosbuvir; SVR12, sustained virologic response at 12 weeks.Source: Afdhal N et al. \u0026amp;lt;em\u0026amp;gt;N Engl J Med\u0026amp;lt;\/em\u0026amp;gt;. 2014.Reproduced with permission from JM Pawlotsky, MD, PhD.\u0026amp;lt;\/div\u0026amp;gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/2\/F1.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/2\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/48\/2\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16620\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \u003Cp id=\u0022p-12\u0022 class=\u0022first-child\u0022\u003ESOF\/LDV With or Without RBV Effective Treatment for Patients With Genotype 1 HCV\u003C\/p\u003E\u003Cp id=\u0022p-13\u0022\u003EHCV, hepatitis C virus; LDV, ledipasvir; RBV, ribavirin; SOF, sofosbuvir; SVR12, sustained virologic response at 12 weeks.\u003C\/p\u003E\u003Cp id=\u0022p-14\u0022\u003ESource: Afdhal N et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E. 2014.\u003C\/p\u003E\u003Cp id=\u0022p-15\u0022\u003EReproduced with permission from JM Pawlotsky, MD, PhD.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-16\u0022\u003ESimilar results were reported for treatment-experienced HCV patients with compensated cirrhosis [Reddy KR et al. \u003Cem\u003EHepatology\u003C\/em\u003E. 2015]. In previously untreated patients with HCV genotype 1 infection and no cirrhosis, a 12-week multitargeted regimen consisting of a single-tablet coformulation (NS3\/4A PI paritaprevir with ritonavir [paritaprevir-ritonavir], the NS5A inhibitor ombitasvir, and the NS5B nonnucleoside inhibitor dasabuvir) with RBV was highly effective (SVR12, 95% to 98%) and associated with low rates of treatment discontinuation [Feld JJ et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E. 2014].\u003C\/p\u003E\u003Cp id=\u0022p-17\u0022\u003EThe same oral combination regimen of paritaprevir\/ritonavir plus ombitasvir plus dasabuvir, and RBV, for 12 or 24 weeks resulted in high SVR rates among patients coinfected with HCV genotype 1 and HIV-1 whether treated for 12 or 24 weeks [Sulkowski MS et al. \u003Cem\u003EJAMA\u003C\/em\u003E. 2015]. Other studies have reported similar high SVR rates with different combinations of DAA drugs in post\u2013liver transplant patients [Kwo PY et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E. 2014], in patients on opioid substitution therapy [Lalezari J et al. \u003Cem\u003EJ Hepatol\u003C\/em\u003E. 2015], and in treatment-na\u00efve or treatment-experienced patients [Lawitz E et al. \u003Cem\u003ELancet\u003C\/em\u003E. 2014].\u003C\/p\u003E\u003Cp id=\u0022p-18\u0022\u003ESOF plus RBV or SOF plus daclatasvir with or without RBV are options in Europe for treating HCV with genotype 2 or 3 [EASL. \u003Cem\u003EJ Hepatol\u003C\/em\u003E. 2015]. In published trials, overall rates of SVR12 were higher in patients with genotype 2 than in those with genotype 3 infection and those without cirrhosis compared with those who had cirrhosis [Lawitz E et al. \u003Cem\u003EHepatology\u003C\/em\u003E. 2015; Nelson DR et al. \u003Cem\u003EHepatology\u003C\/em\u003E. 2015; Jacobson M et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E. 2013; Lawitz E, Gane EJ. \u003Cem\u003EN Engl J Med\u003C\/em\u003E. 2013].\u003C\/p\u003E\u003Cp id=\u0022p-19\u0022\u003EGenotype 4 virus accounts for about 13% of global HCV infections [H\u00e9zode C et al. \u003Cem\u003ELancet\u003C\/em\u003E. 2015]. Ombitasvir and paritaprevir\/ritonavir, given with or without RBV to HCV patients, had high SVR rates at 12 weeks in treatment-na\u00efve and experienced patients with HCV genotype 4 infections. HCV genotype 4 can also be effectively treated with a single-tablet formulation of SOF and LDV (SOF\/LDV), achieving an SVR12 of 95% [Kapoor R et al. AASLD 2014 (abstr 240)], and genotype 6 HCV responds to SOF\/LDV with or without RBV [Gane EJ et al. AASLD 2014 (abstr LB11)].\u003C\/p\u003E\u003Cp id=\u0022p-20\u0022\u003ESeveral issues, such as drug-drug interactions, the timing of therapy in the pretransplant setting, treating patients with renal insufficiency, developing retreatment strategies, and possible resistance to DAAs in patients who fail treatment with DAAs, need to be addressed to achieve global treatment goals. For instance, simeprevir (an oral NS3\/4A PI) is usually effective in combination with other anti-HCV drugs [Jensen DM et al. AASLD (abstr 45)]. However, baseline NS3 polymorphisms at positions associated with reduced in vitro susceptibility to simeprevir have been linked to the emergence of high-level resistance mutations and treatment failure [Lenz O et al. \u003Cem\u003EJ Hepatol\u003C\/em\u003E. 2015].\u003C\/p\u003E\u003Cp id=\u0022p-21\u0022\u003EProf Pawlotsky concluded that it is not feasible to eradicate an infection present in \u0026gt;\u2005130 million individuals by antiviral therapy alone. Control of HCV infection should be the goal in regions that can afford it, as there are currently no HCV vaccines available. For global control to be effective, the transmission of HCV must be prevented, and individuals infected with HCV need to be identified by appropriate screening practices.\u003C\/p\u003E\u003Cp id=\u0022p-22\u0022\u003EUnder the 2001 French HCV screening strategy, all blood donors and individuals with HCV risk factors (eg, drug users, hemodialysis patients, HIV-positive individuals, those having prison records, and individuals with alanine aminotransferase elevations) should be screened. Tools for screening include point-of-care or dried blood spot tests. The focus should be on seeking out undiagnosed, seropositive individuals. Despite being curable, major issues remain regarding cost of care and access to care in low- and middle-income areas.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2015 SAGE Publications\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/15\/48\/2.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_figures.js?nzllgp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzllgp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_tables.js?nzllgp\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}